Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01197534 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Disease Modifying Anti-rheumatic Drug (DMARD) But Not Responding.
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 913
- Enrollment target
NCT01197534 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 913 participants.
The verdict
NCT01197534, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 913 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the effectiveness of two dosing regimens of fostamatinib compared to placebo, in patients with rheumatoid arthritis (RA) who are taking disease modifying anti-rheumatic drug (DMARD) but not responding. The study will last for 1 year.
Interventions
- DRUG fostamatinib
- DRUG placebo, fostamatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 913 participants |
| Start Date | 2010-09 |
| Est. Completion | 2013-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01197534
The ClinicalTrials.gov registry entry for NCT01197534 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 913 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which fostamatinib is the first listed.
NCT01197534 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01197534 about?
NCT01197534 is a clinical study titled "Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Disease Modifying Anti-rheumatic Drug (DMARD) But Not Responding.". The purpose of the study is to evaluate the effectiveness of two dosing regimens of fostamatinib compared to placebo, in patients with rheumatoid arthritis (RA) who are taking disease modifying anti-rheumatic drug (DMARD) but not responding. The study will last for 1 year.
What is the current status of trial NCT01197534?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 913 participants. The study started on 2010-09. Estimated completion is 2013-03.
What interventions are being tested in trial NCT01197534?
The interventions under investigation include: fostamatinib (DRUG), placebo, fostamatinib (DRUG).
Who is sponsoring clinical trial NCT01197534?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.